Recipients With Limited Bimodal Benefit: HA or CROS

Cochlear Implant Clinical Trial

Official title:

Recipients With Limited Bimodal Benefit: HA or CROS

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04155138
• Other study ID #: CRRF 842
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 1, 2019
• Est. completion date: March 20, 2021

Study information

• Verified date: November 2019
• Source: Ottawa Hospital Research Institute
• Contact: Debora L Hogan, M.Sc.N.
• Phone: 6137378899
• Email: dhogan[@]ohri.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The rationale is to determine (in individuals with limited perceived bimodal benefit) whether the CROS device may be a better solution for obtaining two-sided input. If yes, this study would be practice-changing.

Description:

It is well accepted that bilateral input can significantly improve speech understanding in noise for patients with cochlear implants. For cochlear implant (CI) recipients who have a CI on only one side, two sided input can be provided with simultaneous use of a hearing aid (HA) or a CROS device on the opposite side. The decision about which device to use depends on the level of residual hearing a recipient has in non CI-implanted ear, and more specifically what level of useable residual hearing s/he has. Access to useable low frequency hearing can not only improve speech understanding in noise, it can also improve sound quality, pitch perception and music perception.

Clinicians can reasonably predict that a recipient with hearing thresholds better than 60 dB HL at low frequencies (below 750 Hz) would benefit from amplification. For recipients with no measurable acoustic hearing in the contralateral ear, CROS would be a reasonable option, especially if bilateral implantation is not feasible or desired. However, it is more difficult to predict the appropriate device in individuals who have some measurable acoustic hearing but may be receiving limited benefit from it. This can be especially challenging because audiometric thresholds are not a reliable predictor of bimodal benefit. Additionally, acoustic hearing can provide subjective benefits which could hold different intrinsic value or significance for different individuals depending on their life style and listening needs.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 15
• Est. completion date: March 20, 2021
• Est. primary completion date: December 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults (> 18 years of age)

• Unilaterally implanted with an Advanced Bionics implant (CII or later)

• At least six months of CI use

• Limited bimodal benefit as perceived by the recipient and/or the clinician

• Participants may or may not currently be using a hearing aid in the unimplanted ear.

• Open set performance with current device configuration:

• =40% AzBio sentence score in quiet (S0) and? (i.e. do both these apply)

If currently bimodal:

• Hearing aid ear only CNC score <50%

• AzBio Scores bimodal benefit <15% increase in score compared to CI only?

• Unaided audiometric threshold of =100 dBHL up to 500 Hz

• Ability and willingness to participate in multiple sets of open speech testing (and ongoing evaluation of HA and CROS benefit)

Exclusion Criteria:

• Patients who are not proficient in English as the AzBio testing is available in English only.

• Patients with agenesis of the contralateral ear

Related Conditions & MeSH terms

• Cochlear Implant
• Deafness
• Hearing Disability
• Hearing Disorders
• Hearing Disorders and Deafness

Intervention

Device:
• Naida Hearing Aid
hearing aid
• Naida Contralateral Routing of Sound Device
This is a device that routes sound to the non-cochlear implanted ear.

Locations

Country	Name	City	State
Canada	The Ottawa Hospital	Ottawa	ON - Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Ottawa Hospital Research Institute	Advanced Bionics

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perception of speech by way of audiogram and AzBio word testing.	Change in perception of speech by way of audiogram (hearing threshold across dB and frequencies) and AzBio word testing (% accuracy).	At Baseline, Week 6 and Week 12
Primary	7 point Likert study-specific scales illuminating subjective feedback of experience using HA or CROS	Change in 7 point Likert study-specific scales illuminating subjective feedback of experience using HA or CROS. 1 (very dissatisfied) to 7 (very satisfied)	At Baseline, Week 6 and Week 12
Primary	Participant narrative illuminating subjective feedback of experience using HA or CROS	Evolution of narrative interview themes illuminating subjective feedback of experience using HA or CROS	At Baseline, Week 6 and Week 12
Secondary	Demographics	Age, Gender, Hearing History	At Baseline